Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

BACKGROUND AND OBJECTIVES: Short-term studies focused on once-monthly paliperidone palmitate (PP) at doses of 25 mg eq, 50 mg eq, 75 mg eq, 100 mg eq, or 150 mg eq have shown its efficacy and tolerability in the treatment of schizophrenia patients. However, few open-label and long-term studies are a...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Rodríguez, Alexandre, Catalán, Rosa, Penadés, Rafael, Garcia-Rizo, Clemente, Bioque, Miquel, Parellada, Eduard, Bernardo, Miquel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459629/
https://www.ncbi.nlm.nih.gov/pubmed/26082620
http://dx.doi.org/10.2147/PPA.S63948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459629/
https://www.ncbi.nlm.nih.gov/pubmed/26082620
http://dx.doi.org/10.2147/PPA.S63948

Ejemplares similares